Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has signed a worldwide, exclusive license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, B.G. Negev Technologies and Applications Ltd., and Hadasit Medical Research Services and Development Ltd. for BioLineRx to develop and commercialize BL-9020, for the treatment of Type 1 diabetes. Promising results of preclinical studies in a mouse model of Type 1 diabetes demonstrated that BL-9020 is able to inhibit the onset of diabetes. Previously, the project was developed under BioLineRx's Early Development Program as EDP-10.
http://online.wsj.com/article/PR-CO-20131023-905811.html
Wonder if this will help T1.5s and weirdos like me?
http://online.wsj.com/article/PR-CO-20131023-905811.html
Wonder if this will help T1.5s and weirdos like me?